Hypermutated colorectal cancer with POLE/POLD1 variants may benefit from therapy with immune checkpoint inhibitors (ICIs) [12], providing new treatment opportunities for patients carrying POLE/POLD1 variants. The gene discussed is POLE; the disease is colorectal cancer.